Bausch & Lomb Inc.
www.bausch.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Bausch & Lomb Inc.
Bausch + Lomb Separates From Bausch Health After Delivering Its Only First-Quarter Sales Growth
Bausch Health closed Bausch + Lomb IPO offering 10% of shares instead of 20% planned. Bausch + Lomb’s $889m Q1 revenue up 1% while other Bausch Health divisions slumped.
US Ruling Confirms Copaxone Is Not A Biologic
US FDA’s interpretation of ‘protein’ is reasonable and owed deference, the court concludes in tossing Teva suit which challenged Copaxone’s exclusion from list of drugs transitioned to being regulated as biologics.
Copaxone Legal Fight May Finally Be Over As Court Finds The MS Treatment Is Not A Biologic
US FDA’s interpretation of ‘protein’ is reasonable and owed deference, the court concludes in tossing Teva suit which challenged Copaxone’s exclusion from list of drugs transitioned to being regulated as biologics.
Consumer Health Brands On Nielsen ‘Breakthrough’ Leaders List Include Lumify As ‘Superstar’
“We selected Lumify based on its strong business performance in years one and two, and the success it had in growing a category through premiumization," says Nielsen’s BASES leader, Ben Macedo.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
-
Medical Devices
- Diagnostic Equipment & Supplies
- Implantable Devices
- Laser
- Surgical Equipment & Devices
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice